MEDIROM Healthcare Group (MRM) - Rasio rega marang prakiraan pendapatan

Logo grafis MEDIROM Corp (MRM)

Compliance with ESG standards and the digitalization of processes at MEDIROM (MRM) reduce environmental risks, which is supported by the forward P/S multiple. The value of 0.10 determines the latest valuation metric, reflecting the business's adaptation to tax conditions. Growth is driven by expansion in Asia and demand for rehabilitation, while dominance in the Japanese manual therapy market combined with proprietary software ensures the stability of its position.

MRM MEDIROM Healthcare Group: Multiplikator forward rega marang pendapatan ing interval 04.07.2022 - 30.09.2026

Rincian metrik komprehensif lan analitis MEDIROM Corp (MRM)

Analisis kabeh metrik perusahaan:MEDIROM Healthcare Group (MRM)
Produk asli MEDIROM

A steady client flow and the subscription-based system of MEDIROM (MRM) ensure high predictability of cash inflows, rendering the business resilient to market volatility. Analyzing the future P/S multiple on GURU.Markets allows for an assessment of the company's current valuation relative to expected revenue, uncovering trader sentiment cycles and identifying entry points for long-term investment in this asset.

Perusahaan pesaing

Rasio rega marang prakiraan pendapatan HCA Healthcare HCA|Rega forward marang dodolan THC|FMS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Solventum Health|Encompass Health (EHC) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Universal Health Services, Inc.|Rasio rega marang prakiraan pendapatan DaVita|Multiplikator forward rega marang pendapatan RadNet Inc (RDNT)|Rasio rega marang prakiraan pendapatan Option Care Health Inc (OPCH)|SGRY (Surgery Partners Group) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Premier, Inc. PINC|EYE - Multiplikator forward rega marang pendapatan|PGNY: Multiplikator forward rega marang pendapatan|Ardent Health - Rasio rega marang pendapatan sing dikarepake|Select Medical Corp (SEM) - Rasio rega marang prakiraan pendapatan|Astrana Corp - Rega forward marang dodolan|MD (Pediatrix Corp) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep US Physical Therapy Inc USPH|Multiplikator Forward P/S PNTG|Multiplikator Forward P/S Organogenesis Holdings Inc. (ORGO)|Nutex Health Corp - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake AUNA (Auna Corp)|SBC - Rasio rega marang prakiraan pendapatan|evolus.com (EOLS) - Multiplikator forward rega marang pendapatan|CYH: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep BeautyHealth (SKIN)|Rasio rega marang prakiraan pendapatan MediWound Ltd|Kapitalisasi marang prakiraan pendapatan BTMD (Biote Corporation)|Multiplikator forward rega marang pendapatan JYNT (The Joint Corp.)|Rasio rega marang pendapatan sing dikarepake DCGO|Rasio rega marang prakiraan pendapatan P3 Health Partners PIII|GANX - Multiplikator forward rega marang pendapatan|EUDA Health - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Basel Medical Group|CLGN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan CUPR|CCM (Concord Medical) - Multiplikator Forward P/S|American Shared Hospital Services Inc (AMS) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Avalon GloboCare (ALBT)|DHAI (DIH Group) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Longevity Health Holdings XAGE|newgenivf.com (NIVF) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ATIP - Rasio rega marang prakiraan pendapatan|CareMax Inc. (CMAX) - Multiplikator forward rega marang pendapatan|Kindly MD Corp (KDLY) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan ModivCare Corp|Rasio rega marang prakiraan pendapatan Novo Integrated Sciences|SSY: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan IMAC Holdings (BACK)